Angion Biomedica Corp. — Department of Health and Human Services SBIR Phase II: 400
Angion Biomedica Corp. — SBIR Phase II award from Department of Health and Human Services.
Phase II SBIR prototype / development signal
- Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $1,320,083 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Topic code 400 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $1,320,083
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- 400
- Solicitation
- PA15-269
- NAICS
- —
- Place of performance
- NY
- Period
- 2016-04-01 → 2019-03-31
Description
DESCRIPTION provided by applicant The renin angiotensin aldosterone system RAAS plays a critical role in renal physiology Inhibitors of angiotensin converting enzyme ACE or angiotensin receptor blockers ARB are the mainstay in the clinical management of renal disorders such as chronic kidney disease CKD Despite initial success of ACE inhibition or ARB therapy patients often acquire resistance to RAAS inhibitors The clinical significance of the phenomenon of andquot aldosterone breakthroughandquot is increasingly recognized One approach to combat this breakthrough is to inhibit the enzyme responsible for aldosterone production aldosterone synthase Angion has identified a new proprietary non steroidal small molecule inhibitor of aldosterone synthase which shows anti fibrotic effects in preclinical in vivo models f CKD We propose to conduct preclinical development activities towards an IND track nomination of our lead compound for CKD PUBLIC HEALTH RELEVANCE The renin angiotensin aldosterone system RAAS plays a critical role in renal pathophysiology One approach to target this pathway is to inhibit aldosterone synthase the enzyme responsible for aldosterone production Angion has identified a new proprietary non steroidal small molecule inhibitor of aldosterone synthase which shows anti fibrotic effects in preclinical in vivo models of chronic kidney disease We propose to conduct preclinical development activities towards an IND track nomination of our lead compound for chronic kidney disease